Skip to main content

ARCA biopharma Inc

For the period ended Dec 31, 2023. Filed Feb 1, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 1, 2024

ORKA$104.56+1.7%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ARCA biopharma, Inc.
By:/S/ C. Jeffrey Dekker
C. Jeffrey DekkerChief Financial Officer(Principal Financial Officer and Principal Accounting Officer)
Date: February 1, 2024

POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael R. Bristow and C. Jeffrey Dekker, and each of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution for him, and in his name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of ARCA biopharma, Inc., in the capacities and on the dates indicated.

SignatureTitleDate
/S/ Michael R. BristowPresident and Chief ExecutiveFebruary 1, 2024
Michael R. BristowOfficer and Director (Principal Executive Officer)
/S/ C. Jeffrey DekkerChief Financial OfficerFebruary 1, 2024
C. Jeffrey Dekker(Principal Financial Officer and Principal Accounting Officer)
/S/ Linda GraisDirectorFebruary 1, 2024
Linda Grais
/s/ Raymond WoosleyDirectorFebruary 1, 2024
Raymond Woosley
/s/ Robert ConwayDirectorFebruary 1, 2024
Robert Conway
/s/ Daniel MitchellDirectorFebruary 1, 2024
Daniel Mitchell
/s/ Anders HoveDirectorFebruary 1, 2024
Anders Hove
/s/ Jacob Ma-WeaverDirectorFebruary 1, 2024
Jacob Ma-Weaver
/s/ James FlynnDirectorFebruary 1, 2024
James Flynn
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.